Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 12/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 8/20 | 0.61 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5208160 | 0.91 | PTGS2 (0.58) | PTGS2PTGS1NR1H2NR1H3RXRA | |
| SCHEMBL5210903 | 0.91 | PTGS2 (0.63) | PTGS2PTGS1MALT1NR1H2NR1H3 | |
| SCHEMBL5205742 | 0.90 | PTGS2 (0.62) | PTGS2PTGS1NR1H2NR1H3 | |
| SCHEMBL5205833 | 0.88 | PTGS2 (0.69) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL5356064 | 0.86 | PTGS2 (0.63) | PTGS2PTGS1MALT1NR1H2NR1H3 | |
| SCHEMBL6069666 | 0.84 | PTGS2 (0.52) | PTGS2PTGS1NR1H2NR1H3RXRA | |
| SCHEMBL5208155 | 0.84 | PTGS2 (0.71) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL4888052 | 0.84 | PTGS2 (0.81) | PTGS2PTGS1NR1H2NR1H3RXRA | |
| SCHEMBL5360621 | 0.83 | PTGS2 (0.58) | PTGS2PTGS1MALT1NR1H2NR1H3 | |
| SCHEMBL5210900 | 0.82 | PTGS2 (0.78) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040029921-A1 | Substituted pyridines as selective cyclooxygenase-2 inhibitors | MERCK FROSST CANADA & CO. | 2004-02-12 | — | — | US | claimed |
| US-20030065011-A1 | Substituted pyridines as selective cyclooxygenase-2 inhibitors | MERCK FROSST CANADA & CO. | 2003-04-03 | — | — | US | claimed |
| US-20020042375-A1 | Method of treating cancer | HEIMBROOK DAVID C (US) | 2002-04-11 | — | — | US | claimed |
| EP-0912518-A1 | SUBSTITUTED PYRIDINES AS SELECTIVE CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1999-05-06 | — | — | EP | claimed |
| WO-1998003484-A1 | SUBSTITUTED PYRIDINES AS SELECTIVE CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1998-01-29 | — | — | WO | claimed |
| US-7265134-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-09-04 | — | — | US | disclosed |
| EP-1259235-B1 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2007-08-01 | — | — | EP | disclosed |
| US-7186723-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7109204-B2 | controlling signal transduction; anticancer agents, antitumor agents, atherosclerosis, vision defects, antidiabetic agents, antiinflammatory agents | MERCK & CO., INC. (US) | 2006-09-19 | — | — | US | disclosed |
| US-7101884-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-7060715-B2 | Substituted pyridines as selective cyclooxygenase-2 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2006-06-13 | — | — | US | disclosed |
| EP-1404672-B1 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20010044451-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2001-11-22 | — | — | US | disclosed |
| US-6313138-B1 | FOR THERAPY OF ANGIOGENESIS, CANCER, TUMOR GROWTH, ATHEROSCLEROSIS, AGE RELATED MACULAR DEGENERATION, DIABETIC RETINOPATHY, INFLAMMATORY DISEASES IN MAMMALS | MERCK & CO., INC. | 2001-11-06 | — | — | US | disclosed |
| WO-2001062252-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2001-08-30 | — | — | WO | disclosed |
| US-6071936-A | ANTIINFLAMMATORY AGENTS ANTIPYRETICS, ANALGESICS, ANTICARCINOGENIC AGENTS, SIDE EFFECT REDUCTION | MERCK FROSST CANADA & CO. (CA) | 2000-06-06 | — | — | US | disclosed |
| US-6001843-A | Substituted pyridines as selective cyclooxygenase-2 inhibitors | MERCK & CO., INC. (US) | 1999-12-14 | — | — | US | disclosed |
| EP-0912518-A1 | SUBSTITUTED PYRIDINES AS SELECTIVE CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1999-05-06 | — | — | EP | disclosed |
| US-5861419-A | ANTIINFLAMMATORY AGENTS; ANTIPYRETICS, ANALGESICS; ETORICOXIB PATENT | MERCK FROSST CANAD, INC. (CA) | 1999-01-19 | — | — | US | disclosed |
| WO-1998003484-A1 | SUBSTITUTED PYRIDINES AS SELECTIVE CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1998-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042375-A1 | Method of treating cancer | ACP3, KLK3, FOLH1 | PTGS2 14/4885PTGS1 20/4885MALT1 1894/4885 |
| US-20030065011-A1 | Substituted pyridines as selective cyclooxygenase-2 inhibitors | PTGS2, PTGES2, PTGS1 | PTGS2 1/4885PTGS1 3/4885MALT1 659/4885 |
| US-20010044451-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | PTGS2 983/4885PTGS1 791/4885MALT1 2191/4885 |
| US-20040029921-A1 | Substituted pyridines as selective cyclooxygenase-2 inhibitors | PTGS2, PTGES2, PTGS1 | PTGS2 1/4885PTGS1 3/4885MALT1 659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.